Publications

1 Response to combination antiretroviral therapy: variation by age. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study group.
AIDS. 22(12):1463-1473, July 31, 2008

2 Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study.The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group.
Antiviral Ther. 2009; 14(8):1065-74 article

3 Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group AIDS. 2009 Sep 24;23(15):2029-37.

4 Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years.The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
Arch Intern Med. 2010 Mar 8;170:410-419.article

5 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. The Antiretroviral Therapy Cohort Collaboration Study Group (ART-CC).
Clin Infect Dis. 2010 May 15;50(10):1387-96. abstract

6 Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HV infection and a CD4 cell count <200 cells/mL? The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE).
Clinical Infectious Diseases. 2010;51(5):000-000. article

7 HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes. J Bohlius, K Schmidlin, F Boué, G Fätkenheuer, M May, AM Caro-Murillo, A Mocroft, F Bonnet, G Clifford, V Paparizos, JM Miro, N Obel, M Prins, G Chêne, M Egger.
Blood. 2011 Jun 9;117(23):6100-8.

8 Risk of triple-class virologic failure in HIV-infected children. PLATO II project team.
Lancet. 2011 May 7;377(9777):1580-7.

9 Impact of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy - a European multi-cohort study. The EuroCoord-CHAIN joint project. L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kucherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F Garcia, A Judd, K Porter, R Thiébaut, H Castro (née Green), AI van Sighem, C Colin, J Kjær, JD Lundgren, R Paredes, A Pozniak, B Clotet, A Phillips, D Pillay, G Chêne.
Lancet Infectious Diseases. 2011 May;11(5):363-371. Epub 2011 Feb 25.

10 Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. D Costagliola for the PLATO II group for COHERE in EuroCoord.
Lancet Infectious Diseases. doi:10.1016/S1473-3099(11)70248-1. [E-pub ahead of print]

11 All-cause mortality in treated HIV-infected adults with CD4 >500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. C Lewden, V Bouteloup, S De Wit, C Sabin, A Mocroft,JC Wasmuth, A van Sighem, O Kirk, N Obel, G Panos, J Ghosn, F Dabis, M Mary-Krause, C Leport, S Perez-Hoyos, P Sobrino-Vegas, C Stephan, A Castagna, A Antinori,A d’Arminio Monforte, C Torti, C Mussini, V Isern, A Calmy, R Teira, M Egger, J Grarup, and G Chene.
Int. J. Epidemiol. doi: 10.1093/ije/dyr164 [E-pub ahead of print]abstract

12 Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe. F Nakagawa for the PLATO II group for COHERE in EuroCoord.
JAIDS. 2011 Nov 11 [Epub ahead of print].

Updated: 19 Dec 2011